CN101466362A - 对皮肤具有抗老化效果的口服组合物 - Google Patents
对皮肤具有抗老化效果的口服组合物 Download PDFInfo
- Publication number
- CN101466362A CN101466362A CNA2007800217967A CN200780021796A CN101466362A CN 101466362 A CN101466362 A CN 101466362A CN A2007800217967 A CNA2007800217967 A CN A2007800217967A CN 200780021796 A CN200780021796 A CN 200780021796A CN 101466362 A CN101466362 A CN 101466362A
- Authority
- CN
- China
- Prior art keywords
- compositions
- weight
- skin
- carotenoid
- collagen protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 126
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 14
- 108010035532 Collagen Proteins 0.000 claims abstract description 30
- 102000008186 Collagen Human genes 0.000 claims abstract description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 26
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 24
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 24
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims abstract description 15
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims abstract description 15
- 230000004481 post-translational protein modification Effects 0.000 claims abstract description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 14
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 13
- 239000011669 selenium Substances 0.000 claims abstract description 13
- 239000011701 zinc Substances 0.000 claims abstract description 13
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 13
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 30
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 30
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 28
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 28
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 28
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 28
- 239000000194 fatty acid Substances 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 244000068988 Glycine max Species 0.000 claims description 15
- 235000010469 Glycine max Nutrition 0.000 claims description 15
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 15
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 15
- 235000008696 isoflavones Nutrition 0.000 claims description 15
- 239000003995 emulsifying agent Substances 0.000 claims description 14
- 239000007767 bonding agent Substances 0.000 claims description 13
- 102000015694 estrogen receptors Human genes 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 12
- 235000011649 selenium Nutrition 0.000 claims description 12
- 235000016804 zinc Nutrition 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 11
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 239000001751 lycopene Substances 0.000 claims description 11
- 235000012661 lycopene Nutrition 0.000 claims description 11
- 229960004999 lycopene Drugs 0.000 claims description 11
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 11
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 239000011648 beta-carotene Substances 0.000 claims description 10
- 235000013734 beta-carotene Nutrition 0.000 claims description 10
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 10
- 229960002747 betacarotene Drugs 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000013355 food flavoring agent Nutrition 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 7
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 abstract description 11
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 102000005962 receptors Human genes 0.000 abstract description 3
- 108020003175 receptors Proteins 0.000 abstract description 3
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 2
- 239000011668 ascorbic acid Substances 0.000 abstract description 2
- 229960005070 ascorbic acid Drugs 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 235000003687 soy isoflavones Nutrition 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 235000006539 genistein Nutrition 0.000 description 15
- 229940045109 genistein Drugs 0.000 description 15
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 15
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 15
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 108010073771 Soybean Proteins Proteins 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000021323 fish oil Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000197 pyrolysis Methods 0.000 description 6
- 235000019710 soybean protein Nutrition 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- -1 ascorbyl ester Chemical class 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000037067 skin hydration Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 108090000668 Annexin A2 Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001274189 Pomatomus saltatrix Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001314 profilometry Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
适用于口服的组合物,该组合物包括:(i)PPAR配体;例如EPA或DHA(ii)***受体结合剂;例如大豆异黄酮(iii)参与胶原蛋白的翻译后修饰的试剂;例如抗坏血酸和(iv)类胡萝卜素,其中所述组合物基本上不含加入的锌和/或硒,可提供对皮肤的抗老化效果并可用于提高在皮肤中胶原蛋白合成。
Description
本发明涉及适用于口服的组合物和该组合物与某些相关组合物的用途。
对改善人皮肤的外观和触觉已经给予了很大的研究努力。但是,绝大部分可商购产品通过在皮肤的外表起作用来解决此问题。最常用的形式为局部护肤霜(topical skin cream)。但是,这种局部应用具有其限制性并主要处理死的皮肤表层。已知某些成分通过被摄食可以提供皮肤外表和肌理的改善。因此,这些成分从皮肤的内部起作用,并因此可以通过进入活体内部为改善皮肤提供更大的可能。而且,这种效果由于在性质上比局部应用更有效或更医学而可以被公众认识到。
已知膳食鱼油通过摄食传送对UVR-诱发红斑的显著的防护。
当口服诱导时(induced orally),类胡萝卜素,如番茄红素和β-胡萝卜素也已表现出对UVR-诱发红斑给予显著的防护。
同样,维生素E与C相结合口服时,也已显示出提供保护防止UVR-诱发红斑。
US 6,589,535(Johnson & Johnson)披露了营养补充物,其包含富含ω-3和ω-6脂肪酸的油与类胡萝卜素的结合以防止外源物对皮肤的有害影响,特别是对皮肤的免疫***。然而,这限于食品补充剂(foodsupplements),如胶囊或片剂,并没有披露这些材料如何可以通过饮料或其他食品进行递送。黑醋栗种子油是优选的脂肪酸的来源,但这种包含了效力较小的ω-3PUFA α-亚麻酸,而不像鱼油那样整体上(overall)富含ω-3PUFA’s。
US2003/0082275公开了一种贮藏稳定的可饮用的ω-3制剂。公开的饮料包含非常高含量的油并因此是不稳定的,经贮藏形成了两相的饮料。示例性的饮料具有4wt%的油,提供1.6wt%的ω-3浓度。蛋黄是用来作为乳化剂,其中包含大约8wt%卵磷脂。
我们的共同未决的国际申请PCT/EP2005/011658涉及稳定的可消费的乳化液。
WO 02/074308描述了用于预防骨质疏松症的组合物,其包括异黄酮和多不饱和脂肪酸的结合。
美国5,976,606涉及用于获得含DHA的豆腐或豆奶饮料的方法。其目的在于避免鱼油的不希望的口味和/或气味。
EP-A-1340427披露了包含EPA和/或DHA的酸性乳。该文件旨在提供对氧化和相分离稳定的制剂。
DE-U-20304752披露了一系列的营养的抗氧化制剂,其包含许多不同组分,包括锌,硒,番茄红素,维生素C,维生素E,葡萄籽提取物和ω-3脂肪酸。
仍然需要可以对皮肤提供有益的抗老化效果的组合物。特别地,需要可以对皮肤实现提高的效果的组合物。
根据本发明,提供了适用于口服并且能够在消费者的皮肤中提供抗老化效果的组合物,其是含水乳化液,悬浮液或分散液的形式,包括:
(i)PPAR配体;
(ii)***受体结合剂;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)类胡萝卜素,
其中所述组合物基本上不含添加的锌和/或硒,条件是当组合物是包含至
少0.01%重量的食品级磷脂乳化剂的含水乳化液,二十二碳六烯酸
(DHA)和二十碳五烯酸(EPA)在组合物中的总量大于0.6%重量或小于0.024%重量。
在另一个方面,本发明提供了适合于口服的组合物用于获得对皮肤的抗老化效果的用途,该组合物包括:
(i)PPAR配体;
(ii)***受体结合剂;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)类胡萝卜素,
其中所述组合物基本上不含加入的锌和/或硒。
在又一个方面,本发明提供了适用于口服的组合物用于提高皮肤中胶原蛋白的合成的用途,该组合物包括:
(i)PPAR配体;
(ii)***受体结合剂;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)类胡萝卜素。
优选地,所述组合物基本上不含加入的锌和/或硒。
本发明还提供了一种在人或非人类的哺乳动物(优选为人)的皮肤中获得抗老化效果的方法,其包括向人或非人类的哺乳动物提供一定量的对获得所述抗老化效果是有效的本发明的组合物。本发明还提供了一种增加在哺乳动物(优选为人)的皮肤中的胶原蛋白合成的方法,其包括向人或非人类的哺乳动物提供一定量的对获得所述提高的胶原蛋白合成是有效的本发明的组合物。通常,服用所述组合物数周或数月后,所述效果是明显的。
PPAR配体
过氧化物酶体增殖物-激活受体(本文简写为PPAR)是控制脂质代谢的转录因子。PPAR配体是已知的并被描述在例如WO 02/102337中,其内容在此被引入以供参考。
优选地,PPAR配体包含ω-3脂肪酸(即,具有12至26个碳原子的不饱和羧酸)。优选的ω-3脂肪酸是选自DHA,EPA及其混合物的那些。
通常,ω-3脂肪酸以组合物的0.001重量%至10重量%的量存在于组合物中。更优选的量为0.01重量%至5重量%,例如0.1重量%至1重量%或0.1至0.5重量%。
优选地,ω-3脂肪酸以鱼油的形式存在,或来自微生物源。ω-3脂肪酸可以是游离酸,C1-C6的烷基酯,甘油酯(包括甘油单,二和三酯)或其混合物的形式。优选地,ω-3脂肪酸是甘油酯的形式(例如,甘油三酯)。在本文中,提到的ω-3脂肪酸是指游离酸或烷基酯或甘油酯或其混合物。
优选的ω-3脂肪酸是DHA和EPA。
DHA是ω-3、多不饱和、22-碳脂肪酸。其还大量存在于某些鱼(如金枪鱼和蓝鱼)和海洋动物油中。
通常,本发明组合物中的DHA的量为组合物的0.001重量%至10重量%。更优选地为0.01重量%至5重量%,例如0.1重量%至1重量%或从0.1至0.5重量%。
在一个可选择的实施方案中,所述组合物可以包含小于0.2重量%的包含DHA的油。在另一可选择的实施方案中,所述组合物可以包含大于5重量%的包含DHA的油。
DHA可以与EPA一起存在。
二十碳五烯酸(EPA)是人体所用的几种ω-3脂肪酸中的一种。增加的EPA的摄入已被证明对冠心病,高血压,和炎症性疾病,如类风湿关节炎是有益的。
二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)来自冷水性鱼类,如野生鲑鱼(非渔场养殖)、鲭鱼、沙丁鱼、鲱鱼和其他北部海洋动物。鱼类可以用ω3必需脂肪酸、α-亚麻酸(LNA)中生产EPA和DHA,但其许多EPA和DHA从自碳水化合物-糖,淀粉,纤维素等制造EPA和DHA的褐藻和红藻类获得。
最近,为了EPA和DHA,褐藻和红藻已开始商业化种植。它们制造10至14%的长链ω3(基于干重),并可用作包含EPA和DHA的甘油三脂的食物来源。
当DHA和EPA两者存在于本发明的组合物中时,DHA与EPA的重量比为典型地是为1:10到10:1,更优选地为5:1到1:5,甚至更优选地为3:1至1:3,如从1:1到1:2。
***受体结合剂
本发明的组合物包含***受体结合剂。所述***受体结合剂优选为天然产物或其衍生物或提取物。
优选地,所述***受体结合剂包含一种或多种大豆异黄酮。优选的大豆异黄酮是染料木黄酮。
优选地,本发明的组合物包含0.0001重量%到0.1重量%的染料木黄酮,更优选地,从0.001重量%至0.05重量%,甚至更优选地,从0.005重量%至0.04重量%,最优选地,从0.005重量%至0.025重量%,如从0.01重量%至0.025重量%。
优选地,所述组合物包含从0.0002到0.2wt%的大豆异黄酮。这相当于20到200毫克/100g的所述组合物。优选地,所述组合物包含从0.02至0.05wt%的大豆异黄酮。
所述染料木黄酮可以是糖基化或非糖基化的形式,或这两种形式混合物。在本说明书全文中提到的染料木黄酮是指糖基化或非糖基化的形式,或这两种形式的混合物,除非另外具体指出。染料木黄酮的量是基于非糖基化形式(即,如同任何糖基化染料木黄酮为非糖基化)计算得出的。优选地,染料木黄酮作为天然产物或其提取物或浓缩物的组分存在于本发明的组合物中。优选地,天然产品是大豆或红苜蓿,更最选为大豆。
染料木黄酮,当它来自大豆,优选地通过去除大豆蛋白至少在一定程度上被纯化。因此,优选地,本发明的组合物包含小于1重量%的大豆蛋白,更优选地小于0.5重量%的大豆蛋白,甚至更优选地小于0.1重量%的大豆蛋白,如小于0.01重量%或小于0.001重量%或小于0.0001重量%。本发明的组合物可以不含大豆蛋白或基本上不含大豆蛋白。
参与胶原蛋白的翻译后修饰的试剂
本发明的组合物包含为参与胶原蛋白的翻译后修饰的试剂(例如,化合物)的组分。优选地,所述试剂是脯氨酸残基的羟基化中的辅因子。
优选地,参与胶原蛋白的翻译后修饰的试剂是维生素C。
典型地,维生素C以0.01重量%至1重量%的量存在于本发明的组合物中,更优选地,0.05重量%至0.5重量%,最优选地,0.1重量%至0.3重量%。
类胡萝卜素
本发明的组合物包含一种或多种类胡萝卜素。
优选地,组合物包含0.0005到0.1wt%的类胡萝卜素。这相当于0.5至100毫克/100g。优选地,所述组合物包含0.002至0.04wt%的类胡萝卜素。为油溶性的类胡萝卜素,将主要包含于油相中。高度优选的类胡萝卜素是β-胡萝卜素和番茄红素。这些类胡萝卜素提供对UV诱导红斑的适度防护,这认为是由于其抗氧化功能,包括清除活性氧物种的功能。
优选地,类胡萝卜素选自β-胡萝卜素、番茄红素及其混合物。
典型地,类胡萝卜素是以0.001重量%至0.1重量%的量存在,更优选是0.01重量%至0.05重量%。
任选组分
本发明的组合物可包含一种或多种其他的组分。优选的任选的其他组分包括选自抗氧化剂、调味剂、防腐剂和稳定剂及其它们的组合的那些。
优选地,所述组合物包含一种或多种选自抗氧化剂、调味剂、防腐剂和稳定剂的其他组分。
优选地,本发明组合物具有的pH值为3至5,例如3至4。
优选地,在本发明的组合物中存在一种或多种抗氧化剂,以防止或减缓可氧化材料如任何ω-3脂肪酸的自然氧化降解。腐臭鱼油不仅有一种不愉快的味道,甚至可能产生负面的健康影响(Kubow S.,“Toxicityof dietary lipid peroxidation products”,Trends in Food Science &Technology,九月,67-71(1990))。
合适的抗氧化剂可以,尽管并不排除其他地,单独或组合地,选自以下名单:TBHQ,抗坏血酸酯(如抗坏血酸棕榈酸酯),抗坏血酸,维生素E,迷迭香提取物,水果浓缩物或提取物,红茶或绿茶提取物,没食子酸丙酯,精油(essential oil)或油性树脂,丁基化羟基苯甲醚(BHA),丁基化羟基甲苯(BHT),柠檬酸或酯类,辅酶Q10,生育三烯酚(tocotrienols),螯合剂(如EDTA),载体,多酚类化合物,酚类化合物,黄酮类化合物(flavonoids),氧清除剂。
特别优选的抗氧化剂是维生素E。
应加入足以防止ω-3脂肪酸在超过通常6个月的贮藏期间变腐臭的量的抗氧化剂。很显然抗氧化剂的量将取决于所使用抗氧化剂的种类和活性。
为了这些目的,使用适当的试验(例如,Trolox当量抗氧化剂能力)测定抗氧化剂活性。
优选地,本发明的组合物包含调味料。合适的调味剂可以是天然的或合成的。可能需要调味料以使产品对于服用更可口。
在另一实施方案中,本发明的组合物包含少于50%重量的水和/或基本上不含防腐剂和/或调味料。
优选地,所述组合物包含至少0.01wt%的食品级磷脂乳化剂。优选地,所述乳化剂以0.05至3wt%,更优选0.1到1wt%的量存在。
磷脂乳化剂被认为是非常合适的。
可能需要食品级磷脂乳化剂以使组合物稳定为水包油乳化液。优选的磷脂乳化剂是卵磷脂。磷脂乳化剂是油溶性的,但在乳化之前,卵磷脂可以被添加到任何相。优选地,将其加入到含水相。
在另一实施方案中,本发明的组合物包含小于0.01重量%的食品级磷脂乳化剂。
本发明的组合物是一般每日食用1到4次(优选每天一次)。
本发明的组合物基本上不含加入的锌和/或硒。本发明的组合物可包含来自组合物的可商购组分的微量的锌和/或硒,但不包含其金属或盐形式的加入的锌或硒。因此,本发明的组合物可以,例如,分别地包含小于0.5mg的锌和/或小于0.01mg的硒或小于0.0005%的锌和小于0.00001%的硒,更优选地,小于0.0001%的锌和小于0.000005%的硒。
本发明的特定组合物包括以下内容:
组合物,包含:
(i)ω-3脂肪酸,优选DHA和/或EPA;
(ii)染料木黄酮,优选来自大豆异黄酮;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)类胡萝卜素。
组合物,包含:
(i)ω-3脂肪酸,优选DHA和/或EPA;
(ii)***受体结合剂;
(iii)维生素C;和
(iv)类胡萝卜素。
组合物,包含:
(i)ω-3脂肪酸,优选是DHA和/或EPA;
(ii)***受体结合剂;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)番茄红素和/或β-胡萝卜素。
组合物,包含:
(i)ω-3脂肪酸,优选DHA和/或EPA;
(ii)染料木黄酮,优选来自大豆异黄酮;
(iii)维生素C;和
(iv)类胡萝卜素。
组合物,包含:
(i)ω-3脂肪酸,优选DHA和/或EPA;
(ii)染料木黄酮,优选来自大豆异黄酮;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)β-胡萝卜素和/或番茄红素。
组合物,包含:
(i)ω-3脂肪酸,优选DHA和/或EPA;
(ii)染料木黄酮,优选来自大豆异黄酮;
(iii)维生素C;和
(iv)β-胡萝卜素和/或番茄红素。
组合物,包含:
(i)PPAR配体;
(ii)染料木黄酮,优选来自大豆异黄酮;
(iii)维生素C;和
(iv)类胡萝卜素。
组合物,包含:
(i)PPAR配体;
(ii)染料木黄酮,优选来自大豆异黄酮;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)β-胡萝卜素和/或番茄红素。
组合物,包含:
(i)PPAR配体;
(ii)染料木黄酮,优选来自大豆异黄酮;
(iii)维生素C;和
(iv)β-胡萝卜素和/或番茄红素。
本发明的组合物中(i)与(ii)的重量比优选是从100:1至1:10,更优选是从50:1至1:1,甚至更优选是从40:1至10:1。
产品形式
本发明的组合物是可食用的并优选是水基型,即包含至少50wt%的水,优选是至少60wt%或甚至至少70wt%的水。它可以是液体或冷冻的。因此,该产品具有常规水基产品的感觉,并可在规律基础上作为消费者的正常饮食的部分食用。例如,它可代替通常在早餐时间饮用的果汁。
本发明的组合物可以采取任何适当的形式,包括:例如,食品和营养补充品。可根据本发明使用的用于口服的组合物包括饮料,块状食品(bar)和其他液体和固体的形式,例如片剂、丸剂、胶囊和粉末(其可能包含结晶材料),以及涂抹食品、人造黄油、奶油、调味汁、调味品、蛋黄酱、冰淇淋、馅料、糖食和谷类食物。
优选地,本发明的组合物是基本上均匀的含水乳化液、悬浮液或分散液的形式。
本发明的组合物优选作为饮料进行包装。
优选地,在剪切速率1s-1和25℃下,所述组合物具有2至100厘泊的粘度。
本发明的组合物可以从含水相和油相进行准备。一般来说,是把水溶性成分在含水相中放在一起和把油溶性成分在油相中放在一起。乳化剂是例外。已经令人吃惊地发现,油溶性的乳化剂在其被加入含水相中时提供了更加稳定的乳化液。
然后将这两相在常规乳化剂设备中混合在一起。制得的乳化液是贮藏稳定的,且油不会几个月变腐臭。
然后,油相和含水相混合在一起,形成均匀稳定的乳化液。
在一个优选方法中,所述油是在粉末载体材料上,以协助乳化液的形成。
然后,稳定的乳化液可以在密封的容器如金属、涂布的纸板(例如,利乐包(tetra Pak))或塑料容器中进行包装。然后,优选地,所述容器被密封,从而不提供顶部空间或气体(如氮气或二氧化碳)填充的顶部空间。这还有助于进一步防止氧化。
可选择地,乳化液可作为冷冻食用产品被冷冻,包装和销售。
发明的用途
优选地,本发明的组合物能提高皮肤中的胶原蛋白合成。
所述组合物可以对皮肤产生抗老化效果。术语“抗老化”是指皮肤会显示出较少的皱纹(即,有对皱纹和/或细纹(fine line)的抗皱效果,包括减少皱纹深度),和所述组合物可赋予一种或多种对皮肤进一步的选自以下的益处:降低的干燥度;提高的紧致性(firmness);增加弹性;增加光滑度;更洁净的皮肤;更少斑点、粉刺和瑕疵(包括痤疮);更洁净的皮肤;较少敏感的皮肤;和通常更健康的皮肤。
本发明的组合物通过提高在皮肤中的胶原蛋白合成可显示出抗老化效果,且本发明的组合物可以用于提高胶原蛋白合成(作为抗老化效果的一部分或与抗老化效果相独立);优选地,胶原蛋白合成至少提高了10%,更优选至少20%,例如至少25%重量(例如基于合成的胶原蛋白的重量确定的,优选经过14周的期间)。
所述皮肤可以包括整个身体的皮肤,优选面部,颈部和/或手。所述皮肤还可包括头皮皮肤,对于头发(包括降低的老化)和头皮发痒或刺激具有益处。
以下非限制性实施例说明本发明并且不以任何方式限制其范围。在实施例和本说明书全文中,所有的百分比,部分和比例,除非另外指出,否则以重量计。
实施例
测定胶原蛋白合成的提高
实验方法概要
开发生化试验和蛋白质提取方法以确定在皮肤中新胶原蛋白合成的变化。
a.在干预期(intervention period)的初始期间(baseline)(T1)和结束时(T15)进行皮肤活组织检查。
b.在每一个时间点,获取两次3mm钻取(punch)活组织检查样品(4mm深),放置在低温保存管(cryotube)容器中,并立即冻存于液氮中。
c.然后将这些活组织检查样品(biopsies)于-80℃保存。
材料和方法
细胞裂解液(cell lysate)的制备
所有钻取活组织检查样品被放置在具有1ml细胞裂解缓冲剂的杜恩斯匀化器(dounce homogeniser)并彻底地磨碎(以致没有残留明显的皮肤块或细胞外基质)。所述裂解液缓冲剂在pH为7.6下包含1%的NP-40,0.1%脱氧胆酸钠,0.1%的SDS,6mM氯化钠和0.05M的Tris。在使用前,以10μl每毫升的裂解缓冲剂的水平加入蛋白酶抑制剂合剂(protease inhibitior cocktail)(1000X;Sigma P8340)。在组织的完全均匀化后,接着在20,000克在4℃下通过离心20分钟去除不需要的细胞碎片。在-80℃下冷冻澄清的细胞裂解液直到需要使用。
总蛋白检测(Pierce)
使用Pierce BCA蛋白检测试剂盒测定每个细胞裂解液的总蛋白浓度。由所提供的2mg/ml BAS储备溶液制备一组8个在0至1200μg/ml之间的蛋白的标准溶液。在平底96孔微量滴定板的双孔(duplicate wells)中加入10μl的标准或细胞裂解液。所述试剂溶液是按照试剂盒的指示由50份试剂A和1份试剂B制备的。在每个微量滴定板的孔中加入200μl的最终试剂。所述板在37℃下混合、覆盖和培养30分钟,在562nm读出吸收值。构造蛋白标准曲线并用于确定每一个细胞裂解液的蛋白浓度。
前胶原IC-肽EIA KIT(Takara Bio Inc.)
胶原蛋白I是作为前体分子(前胶原I)合成的。因此,游离前肽(free propeptide)的量在化学计量上反映所合成的胶原蛋白I的量。I型前胶原C-肽酶免疫测试(EIA)试剂盒(Procollagen Type I C-peptideEnzyme Immunoassay(EIA)kit)可定量测定I型前胶原C-肽(PIP)。
在浓度范围为0到640ng/ml的样品稀释液中制备8个PIP标准物(standard)。在双孔中加入100μl的抗体-过氧化物酶缀合溶液和20μl的细胞裂解液(1μg蛋白)或标准物。密封该板,并在37℃下培养3个小时,然后以400μl的PBS洗涤4次。然后每个孔加入100μl的基质溶液,所述板在室温条件下在工作台面上培养15分钟。此后,向每个孔加入100μl停止液,以酶标分析仪(plate reader)在450nm测量吸收。
绘制平均吸收率对PIP浓度的标准曲线和通过回归分析计算的最好拟合线。由此估计所有的样品中PIP的未知浓度。
测量皮肤水合
Fluhr等,Skin Res Technol 1999;5:161-170已经总结了用于确定角质层的水合状态的各种方法。简言之,角质含水量测定仪(Corneometer)(Courage & Khazaka)通过检测表皮容量测量皮肤水合。该探测器是由彼此接近的两个手指型金属板制成,具有约30毫米的测量深度。该仪器确定角质层的最外部皮肤层的湿度水平。的工作原理是基于被设计为冷凝器形式的检测器的电容的改变。测量头的表面,与皮肤接触,根据皮肤湿度水平的改变其电容。由角质含水量测定仪测得的值的提高是皮肤水合改善的表示。
经表皮水分损失(TEWL)的测量
Wilson & Maibach,(1989)Transepidermal water loss,A review,In:Cutaneous Investigation in Health and Disease,Non-invasive Methods andInstrumentation(Leveque,J.L.,编辑),pp.113-130,Dekker,New York,NY已经进行了对测量TEWL的方法的分析。该皮肤屏障起皮肤中水分平衡的调节器作用。当该屏障被破坏,水交换调节***变得不稳定。这意味着,水更容易地迁移到外部环境,增加经表皮水分损失。皮肤屏障的有效性随着年龄降低。但是,如果皮肤屏障的状况改善了,由于水分交换调节机制恢复其平衡,水分丢失减少了。经表皮水分损失测量可以用Servomed“Evaporimeter”进行。由两个捕获器组成的探测器被水蒸汽流横向穿过。测量在两个捕获器之间的分压差。这个值对应于挥发性物质的蒸发速度(在本案中,是水)。TEWL的降低是皮肤阻隔性能改善的表示。
测量皮肤弹性和紧致性
皮肤弹性和紧致性的测量是使用皮肤弹性仪(cutometer)进行,并在Escoffier等人,J Invest Dermatol,93(3):353-7中得到描述。测量是使用利用真空原理的仪器进行的,吸入(suck up)皮肤表面的界定面积并对其光学记录。对记录的测量曲线的分析可以判断皮肤的弹性和塑性特征。年轻的皮肤显示出高的弹性度和当吸力程序结束后恢复到其原始状态时仅逐步失去形状。年轻、健康、柔软和充分湿润的皮肤将具有比老化干燥、粗糙的皮肤更高的弹性。因此,该皮肤弹性仪给出了一组测量值,它使我们能够量化弹性的特征。该技术在于通过测量探针吸入皮肤。通过装置内产生的负压,皮肤被吸入探针的小孔。皮肤渗入到探针的深度通过非接触式光学测量***测量。该***组成为光源和光接收器以及两个彼此相对的棱镜,其将光从发射机(transmitter)投射到接收器。光强度随皮肤的渗入深度变化。皮肤对被吸入的抵抗提供了皮肤紧致性的指示和皮肤回到其原来位置的能力提供了皮肤弹性的指示。在每次测量的结束时显示曲线,其可以作出对应于皮肤力学性能的几项计算。
细纹、皱纹及皮肤光滑度的分析
如Cook,J Soc Cosmet Chem,1980;31:339-359所述,使用复制物(replica)和皮肤轮廓测量法(skin profilometry)可评价皮肤粗糙度和起皱纹。准备硅橡胶材料如Silflo并施用于所述测试区域。一旦固化(set),将它移出并使用光学轮廓测量法分析。通过这种测量方法,一个平行的条纹图案投射到皮肤表面,并在照相机的CCD芯片上描绘。皮肤表面上的微小的评价差异使平行的投影条纹偏斜,这些偏斜构成了皮肤轮廓的定性和定量测量,3D测量效果由此获得。皮肤轮廓由CCD相机记录、数码化,并传输至测量和评价计算机以定性评价。
实施例1-本发明的组合物
以下是本发明的组合物的例子。
成分 | 重量% |
鱼油(包含12%的DHA和EPA) | 3.2 |
大豆异黄酮(40%) | 0.083 |
维生素C | 0.17 |
维生素E | 0.25 |
番茄红素(20%活性) | 0.027 |
β-胡萝卜素(30%) | 0.008 |
柠檬酸 | 0.18 |
调味料,甜味剂,增稠剂,乳化剂 | q.v. |
水 | 至100% |
通过在水中加入所述组分并均匀化所述混合物来制备所述组合物。
实施例2
在14周内,测试本发明的制剂并给出以下结果:
图1显示在使用所述组合物处理前(图的左手边)和服用组合物14周(图的右手边)后消费者的眼睛周围的皮肤区域的复制物。
图2是如图1的相同类型的并列比较,其是针对消费者的眼睛周围的皮肤的不同部分。
在这两个图1和图2中,在服用本发明组合物后,皱纹的显著减少是显而易见的。
Claims (16)
1.适用于口服并且能够在消费者的皮肤中提供抗老化效果的组合物,其是含水乳化液,悬浮液或分散液的形式,包括:
(i)PPAR配体;
(ii)***受体结合剂;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)类胡萝卜素,
其中所述组合物基本上不含加入的锌和/或硒,条件是当组合物是包含至少0.01重量%的食品级磷脂乳化剂的含水乳化液,二十二碳六烯酸(DHA)和二十碳五烯酸(EPA)在组合物中的总量大于0.6重量%或小于0.024重量%。
2.如权利要求1所述的组合物,其中(i)与(ii)的重量比为100:1至1:10。
3.如权利要求1或2所述的组合物,其中PPAR配体包含ω-3脂肪酸,所述ω-3脂肪酸选自DHA、EPA及其混合物。
4.如权利要求3所述的组合物,其中ω-3脂肪酸以0.01重量%至1.0重量%的量存在。
5.如权利要求1-4中任意一项所述的组合物,其中***受体结合剂包含大豆异黄酮。
6.如权利要求5所述的组合物,其中大豆异黄酮以0.01重量%至0.1重量%的量存在。
7.如权利要求1-6中任意一项所述的组合物,其中参与胶原蛋白的翻译后修饰的试剂是维生素C。
8.如权利要求7所述的组合物,其中维生素C以0.01重量%至1重量%的量存在。
9.如权利要求1-8中任意一项所述的组合物,其中类胡萝卜素选自β-胡萝卜素、番茄红素及其混合物。
10.如权利要求9所述的组合物,其中类胡萝卜素以0.001重量%至0.1重量%的量存在。
11.如权利要求1-10中任意一项所述的组合物,其中该组合物包含一种或多种其他的组分,所述其他组分选自抗氧化剂、调味剂、防腐剂和稳定剂。
12.如权利要求1-11中任意一项所述的组合物,其中该组合物作为饮料进行包装。
13.如权利要求1-12中任意一项所述的组合物,其中该组合物能够提高在皮肤中的胶原蛋白的合成。
14.适用于口服的组合物用于获得对皮肤的抗老化效果的用途,该组合物包括:
(i)PPAR配体;
(ii)***受体结合剂;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)类胡萝卜素,
其中所述组合物基本上不含加入的锌和/或硒。
15.适用于口服的组合物用于增加在皮肤中胶原蛋白的合成的用途,该组合物包括:
(i)PPAR配体;
(ii)***受体结合剂;
(iii)参与胶原蛋白的翻译后修饰的试剂;和
(iv)类胡萝卜素。
16.如权利要求14或15的用途,其中(i)与(ii)的重量比为100:1至1:10。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06252019 | 2006-04-12 | ||
EP06252019.2 | 2006-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101466362A true CN101466362A (zh) | 2009-06-24 |
Family
ID=36603325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007800217967A Pending CN101466362A (zh) | 2006-04-12 | 2007-03-27 | 对皮肤具有抗老化效果的口服组合物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20090239945A1 (zh) |
EP (2) | EP2004160B1 (zh) |
JP (1) | JP2009534317A (zh) |
CN (1) | CN101466362A (zh) |
ES (2) | ES2562977T3 (zh) |
MX (1) | MX2008012998A (zh) |
PL (2) | PL2189155T3 (zh) |
RU (2) | RU2434642C2 (zh) |
WO (1) | WO2007115934A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004108740A2 (en) | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
TR201908522T4 (tr) | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
EP2540292A1 (en) * | 2011-06-28 | 2013-01-02 | Nestec S.A. | DHA and EPA in the reduction of oxidative stress |
GB201121519D0 (en) | 2011-12-14 | 2012-01-25 | Ip Science Ltd | Fat-based food products |
WO2014057522A1 (en) | 2012-10-12 | 2014-04-17 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
AU2013337308B2 (en) | 2012-11-05 | 2018-06-21 | Tdeltas | Ketone bodies to protect tissues from damage by ionizing radiation |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
BR112015023334B1 (pt) | 2013-03-14 | 2021-05-18 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | processo para produção de (r)-3hidroxibutil (r)-3-hidroxibutirato |
SG11201507288UA (en) | 2013-03-15 | 2015-10-29 | Mochida Pharm Co Ltd | Compositions and methods for treating non-alcoholic steatohepatitis |
US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
WO2015053379A1 (en) * | 2013-10-07 | 2015-04-16 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
CN108295120A (zh) * | 2017-09-19 | 2018-07-20 | 陈淑珍 | 一种使***丰满美丽的霜剂 |
JP2019129789A (ja) * | 2018-02-01 | 2019-08-08 | 株式会社ノエビア | 抗ニキビ用食品、髪質改善用食品又は化粧のり改善用食品 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1205043B (it) * | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
US4843095A (en) * | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
JP2732958B2 (ja) * | 1991-05-22 | 1998-03-30 | 鐘紡株式会社 | コラーゲン代謝賦活剤 |
FR2717078B1 (fr) * | 1994-03-08 | 1996-12-13 | Oreal | Utilisation des acides sulfoniques comme agents antivieillissement dans une composition cosmétique ou dermatologique. |
US5567424A (en) * | 1994-06-10 | 1996-10-22 | Reliv International, Inc. | Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption |
DE19615577A1 (de) * | 1996-04-19 | 1997-10-23 | Beiersdorf Ag | Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen |
JP3177947B2 (ja) * | 1996-07-30 | 2001-06-18 | 株式会社ジャニフ・テック | Dha入り豆腐、飲用豆乳およびそれらの乾燥粉末の製造方法 |
US6149939A (en) * | 1997-05-09 | 2000-11-21 | Strumor; Mathew A. | Healthful dissolvable oral tablets, and mini-bars |
AT407821B (de) * | 1998-03-24 | 2001-06-25 | Franz Dr Stueckler | Mittel auf der basis von naturstoffen |
IT1299191B1 (it) * | 1998-06-23 | 2000-02-29 | Sigma Tau Healthscience Spa | Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa |
US6673374B2 (en) * | 1998-07-31 | 2004-01-06 | Howard Murad | Pharmaceutical compositions and methods for managing skin conditions |
WO2000068239A1 (de) * | 1999-05-05 | 2000-11-16 | Henkel Kommanditgesellschaft Auf Aktien | Neue salicylalkohol-derivate |
NO313076B1 (no) | 1999-12-28 | 2002-08-12 | Pronova Biocare As | Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav |
FR2804023B1 (fr) | 2000-01-26 | 2002-09-20 | Johnson & Johnson Consumer Fr | Complement nutritionnel a base d'huile de pepins de cassis |
FR2815864B1 (fr) * | 2000-10-26 | 2003-02-28 | Oreal | Utilisation de l'association d'au moins un carotenoide et de vitamine c pour traiter les signes cutanes du vieillissement |
FR2815859B1 (fr) * | 2000-10-26 | 2003-02-28 | Oreal | Utilisation de l'association d'au moins un carotenoide a activite provitaminique a et d'au moins un carotenoide sans activite provitaminique a pour traiter les signes du vieillissement |
CA2426853A1 (en) | 2000-11-13 | 2003-04-24 | Nippon Suisan Kaisha, Ltd. | Soybean milks containing epa at high concentration and process for producing the same |
FR2821549A1 (fr) * | 2001-03-05 | 2002-09-06 | Oreal | Utilisation d'un carotenoide pour traiter les signes du vieillissement |
KR100875800B1 (ko) | 2001-03-15 | 2008-12-24 | 디에스엠 아이피 어셋츠 비.브이. | 이소플라본과 다가 불포화 지방산의 혼합물을 포함하는골다공증 예방용 조성물 |
GB0111282D0 (en) * | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
GB0114848D0 (en) | 2001-06-18 | 2001-08-08 | Unilever Plc | Antiperspirant or deodorant compositions |
DE20204847U1 (de) | 2002-03-26 | 2002-07-04 | Weber & Weber Gmbh & Co Kg | Mikronährstoffkombinationsprodukt, geeignet für die nutritive Ergänzung als Antioxidanz |
EP1581199B1 (en) * | 2002-09-09 | 2015-02-25 | Nestec S.A. | Orally administrable composition for improving skin quality |
US20040146539A1 (en) * | 2003-01-24 | 2004-07-29 | Gupta Shyam K. | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits |
WO2004068970A2 (en) * | 2003-01-31 | 2004-08-19 | The Procter & Gamble Company | Means for improving the appearance of mammalian keratinous tissue |
PL2218342T3 (pl) * | 2003-05-27 | 2019-01-31 | Dsm Ip Assets B.V. | Nowe kompozycje nutraceutyczne i ich zastosowanie |
JP2005015387A (ja) * | 2003-06-26 | 2005-01-20 | Rohto Pharmaceut Co Ltd | 抗酸化組成物 |
PL1833498T3 (pl) * | 2004-11-29 | 2010-06-30 | Unilever Nv | Doustna kompozycja do polepszania właściwości skóry |
MX2008009574A (es) * | 2006-02-01 | 2008-09-04 | Nestec Sa | Sistema y metodos nutricionales para aumentar la longevidad. |
-
2007
- 2007-03-27 CN CNA2007800217967A patent/CN101466362A/zh active Pending
- 2007-03-27 PL PL10156458T patent/PL2189155T3/pl unknown
- 2007-03-27 EP EP07727391A patent/EP2004160B1/en active Active
- 2007-03-27 EP EP10156458.1A patent/EP2189155B1/en active Active
- 2007-03-27 WO PCT/EP2007/052918 patent/WO2007115934A1/en active Application Filing
- 2007-03-27 MX MX2008012998A patent/MX2008012998A/es active IP Right Grant
- 2007-03-27 JP JP2009504677A patent/JP2009534317A/ja active Pending
- 2007-03-27 ES ES10156458.1T patent/ES2562977T3/es active Active
- 2007-03-27 ES ES07727391T patent/ES2393212T3/es active Active
- 2007-03-27 RU RU2008144576/15A patent/RU2434642C2/ru not_active IP Right Cessation
- 2007-03-27 PL PL07727391T patent/PL2004160T3/pl unknown
- 2007-03-27 US US12/226,158 patent/US20090239945A1/en not_active Abandoned
-
2010
- 2010-04-01 US US12/752,468 patent/US20100190847A1/en not_active Abandoned
- 2010-05-20 RU RU2010120435/15A patent/RU2533277C2/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2008144576A (ru) | 2010-05-20 |
PL2189155T3 (pl) | 2016-07-29 |
MX2008012998A (es) | 2008-10-17 |
EP2189155A1 (en) | 2010-05-26 |
RU2010120435A (ru) | 2011-11-27 |
EP2004160A1 (en) | 2008-12-24 |
RU2533277C2 (ru) | 2014-11-20 |
EP2004160B1 (en) | 2012-09-19 |
US20100190847A1 (en) | 2010-07-29 |
ES2393212T3 (es) | 2012-12-19 |
JP2009534317A (ja) | 2009-09-24 |
EP2189155B1 (en) | 2016-01-06 |
ES2562977T3 (es) | 2016-03-09 |
PL2004160T3 (pl) | 2013-02-28 |
US20090239945A1 (en) | 2009-09-24 |
RU2434642C2 (ru) | 2011-11-27 |
WO2007115934A1 (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101466362A (zh) | 对皮肤具有抗老化效果的口服组合物 | |
US10071073B2 (en) | Compositions containing as the active ingredient components from Salvia sclarea seed | |
RU2396073C2 (ru) | Пероральная композиция для улучшения свойств кожи | |
CN102469828A (zh) | 富含ω-3脂肪酸的饮料 | |
CN102469825A (zh) | 富含ω-3脂肪酸的烘焙食品和棒组合物 | |
US20120083524A1 (en) | Oral Composition Comprising DHA and Genistein for Enhancing Skin Properties | |
Sardiñas-Valdés et al. | Physicochemical and sensory properties of Manchego-type cheese fortified with nanoemulsified curcumin | |
Abed et al. | The effect of adding Pumpkin seed oil on physicochemical and sensory properties of the mayonnaise | |
CN102469826A (zh) | 富含ω-3脂肪酸的汤和调味料 | |
US20140080773A1 (en) | Composition for Delivering an Anti-Ageing Effect on the Skin and a Method for Improving Skin Characteristics | |
CN102325519B (zh) | 处理老化皮肤迹象的可食用组合物 | |
JP2006124488A (ja) | 高度不飽和脂肪酸含有リン脂質の水分散液 | |
Murage | Increasing the consumption of essential long chain fatty acids through fortification of yoghurt with Omega-3 pufa from Nile perch oil | |
Di Memmo | Influence of multiple injections of vitamin E on quality traits and oxydative stability of lamb meat | |
CA2293088A1 (en) | Method and composition for masking taste and odor from fish oil | |
Ohno et al. | A comparative study of serum proteins, lipids, calcium and inorganic phosphorus between Japanese and Dutch university students. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20090624 |